

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

**Ritter Pharmaceuticals, Inc.**

---

(Name of Issuer)

---

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

---

767836109

(CUSIP Number)

---

December 31, 2015

(Date of Event That Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

---

---

1.	NAMES OF REPORTING PERSONS <b>Stonehenge Partners LLC</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION <b>United States</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER <b>817,271</b>
	6.	SHARED VOTING POWER
	7.	SOLE DISPOSITIVE POWER <b>817,271</b>
	8.	SHARED DISPOSITIVE POWER
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <b>817,271</b>	
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> (SEE INSTRUCTIONS)	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) <b>9.5%</b> <sup>(1)</sup>	
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) <b>OO</b>	

<sup>(1)</sup> Based on 8,582,009 shares of Common Stock of the Company outstanding as of December 30, 2015.

1.	NAMES OF REPORTING PERSONS <b>Andrew J. Ritter</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION <b>United States</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER <b>189,541</b> <sup>(1)</sup>
	6.	SHARED VOTING POWER <b>817,271</b> <sup>(2)</sup>
	7.	SOLE DISPOSITIVE POWER <b>189,541</b> <sup>(1)</sup>
	8.	SHARED DISPOSITIVE POWER <b>817,271</b> <sup>(2)</sup>
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <b>1,006,812</b>	
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> (SEE INSTRUCTIONS)	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) <b>11.5%</b> <sup>(3)</sup>	
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) <b>IN</b>	

<sup>(1)</sup> Shares underlying stock option awards that are currently exercisable or exercisable within 60 days of December 30, 2015.

<sup>(2)</sup> As a managing partner of Stonehenge Partners LLC, Andrew Ritter may be deemed the beneficial owner of these shares.

<sup>(3)</sup> Based on 8,582,009 shares of Common Stock of the Company outstanding as of December 30, 2015.

1.	NAMES OF REPORTING PERSONS  <b>Ira E. Ritter</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION  <b>United States</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER  <b>189,541</b> <sup>(1)</sup>
	6.	SHARED VOTING POWER  <b>817,271</b> <sup>(2)</sup>
	7.	SOLE DISPOSITIVE POWER  <b>189,541</b> <sup>(1)</sup>
	8.	SHARED DISPOSITIVE POWER  <b>817,271</b> <sup>(2)</sup>
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  <b>1,006,812</b>	
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/> (SEE INSTRUCTIONS)	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  <b>11.5%</b> <sup>(3)</sup>	
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  <b>IN</b>	

<sup>(1)</sup> Shares underlying stock option awards that are currently exercisable or exercisable within 60 days of December 30, 2015.

<sup>(2)</sup> As a managing partner of Stonehenge Partners LLC, Ira Ritter may be deemed the beneficial owner of these shares.

<sup>(3)</sup> Based on 8,582,009 shares of Common Stock of the Company outstanding as of December 30, 2015.

Item 1(a). Name of Issuer:

**Ritter Pharmaceuticals, Inc. (the "Company")**

Item 1(b). Address of Issuer's Principal Executive Offices:

**1880 Century Park East, #1000  
Los Angeles, CA 90067**

Item 2(a). Name of Person(s) Filing:

**Stonehenge Partners LLC**

**Andrew J. Ritter**

**Ira E. Ritter**

Item 2(b). Address of Principal Business Office, or, if None, Residence:

**The address of Stonehenge Partners LLC is 21800 Oxnard Street, Suite 250, Woodland Hills, California 91367.**

**The address for Andrew J. Ritter and Ira E. Ritter is 1880 Century Park East, #1000, Los Angeles, California 90067.**

Item 2(c). Citizenship:

**Stonehenge Partners LLC is a California limited liability company with its principal place of business in California.**

**Andrew J. Ritter - United States**

**Ira E. Ritter – United States**

Item 2(d). Title of Class of Securities:

**Common Stock, par value \$0.001 per share**

Item 2(e). CUSIP Number:

**767836109**

Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

**Not Applicable**

---

Item 4. Ownership:

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person and is incorporated herein by reference.

As managing partners of Stonehenge Partners LLC, Andrew Ritter and Ira Ritter may be deemed beneficial owners of the shares held by Stonehenge Partners LLC insofar as they may be deemed to share the power to direct the voting or disposition of such shares. Neither the filing of this Schedule 13G, any amendment hereto, nor any of their respective contents shall be deemed to constitute an admission that either of such individuals is, for any purpose, the beneficial owner of such securities, and such beneficial ownership is expressly disclaimed. The filing of this statement should not be construed to be an admission that any of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Act.

Item 5. Ownership of Five Percent or Less of a Class.

**Not Applicable**

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

**Not Applicable**

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported by the Parent Holding Company or Control Person.

**Not Applicable**

Item 8. Identification and Classification of Members of the Group.

**Not Applicable**

Item 9. Notice of Dissolution of the Group.

**Not Applicable**

Item 10. Certification:

**Not Applicable**

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 24, 2016

Stonehenge Partners LLC

By: /s/ Andrew J. Ritter

Name: Andrew J. Ritter

Title: Managing Partner

Date: February 24, 2016

/s/ Andrew J. Ritter

Andrew J. Ritter

Date: February 24, 2016

/s/ Ira E. Ritter

Ira E. Ritter

---



**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them, of this Schedule 13G (including further amendments thereto) with respect to the common stock, par value \$0.001 per share, of Ritter Pharmaceuticals, Inc., and that this Joint Filing Agreement be included as an exhibit to such joint filing.

This Joint Filing Agreement may be executed in one or more counterparts, and each such counterpart shall be an original but all of which, taken together, shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint filing Agreement as of this 23rd day of February 2016.

Stonhenge Partners LLC

By: /s/ Andrew J. Ritter

Name: Andrew J. Ritter

Title: Managing Partner

/s/ Andrew J. Ritter

Andrew J. Ritter

/s/ Ira E. Ritter

Ira E. Ritter

---

